For patients with type 2 diabetes mellitus (T2DM), glucagon-like peptide 1 receptor agonist (GLP-1 RA) use is associated with ...

Objective—Glucagon-like peptide 1 (GLP-1) exerts beneficial antidiabetic actions via effects on pancreatic β- and α-cells. Previous studies have focused on the improvements in β-cell function ...

With brand-name GLP-1s for obesity treatment on and off the shortage list, prescribing can get complicated. Five providers ...

In addition to ensuring equitable access to the glucagon-like peptide-1 (GLP-1) receptor agonists, the medical community ...

GLP-1s, or glucagon-like peptide-1 agonist drugs, are seemingly everywhere. In recent years, this class of weight-loss and Type 2 diabetes medication has become not only a household name but ...

The use of glucagon-like peptide 1 (GLP-1) receptor agonists in adults with type 2 diabetes mellitus (T2DM) was not ...

Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) can decrease the risk for developing early-onset colorectal cancer ...

Medically reviewed by Danielle Weiss, MD After losing extra pounds on Ozempic (semaglutide), some are finding themselves ...

For patients with ischemic stroke, sodium-glucose cotransporter-2 inhibitors (SGLT-2is) and glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are associated with reduced mortality, myocardial ...

HERSHEY, PA. — GLP-1 weight-loss drugs are having a “mild impact” on The Hershey Co.’s business, president and chief ...

Lexaria Bioscience (LEXX) has engaged a contract research organization to perform the world’s first-ever fluorescently tagged ...

Only 13 states currently allow Medicaid to cover treatment of obesity using glucagon-like peptide-1 agonist (GLP-1) medications, researchers said.